Natalia Jura, PhD

Assistant Professor
Cardiovascular Research Institute
Department of Cellular and Molecular Pharmacology
+1 415 514-1133
Research Overview: 

Cells maintain homeostasis by precisely responding to external growth stimuli. Our lab is interested in understanding how cells detect these extracellular growth signals and transmit them across the plasma membrane. A central role in this process is played by receptor tyrosine kinases (RTKs) and the ligand-dependent transition of their kinase domains from the inactive to the active state. The activated kinase domains initiate a phosphorylation cascade that results in activation of downstream signaling pathways. We want to gain a molecular understanding how ligand binding to the extracellular domains of the receptor results in activation of the intracellular kinase domains, how the active receptor establishes its specificity for substrate phosphorylation, and how the multi-protein signaling complexes assemble at the sites of active receptors. Our research will focus on the family of the Epidermal Growth Factor Receptors: EGFR/HER1/ErbB1, ErbB2, ErbB3 and ErbB4, and the MET family of receptor tyrosine kinases. Both receptor families represent leading clinical targets and our long-term goal is to develop new therapeutic strategies for targeting these receptors in human diseases.

Because RTKs are membrane proteins, they are difficult to study in vitro and despite decades of research, the high-resolution structures of the full-length receptors that visualize the connection between the extracellular and intracellular domains are still missing. Our lab will take advantage from the recent technologies that provide a platform for reconstitution of the transmembrane proteins in the membrane environment of lipid nanodiscs and lipid bilayers. We will apply these systems to pursue crystallography of the full-length receptors and their complexes with downstream effectors. We will pair these efforts with biochemical analysis of the reconstituted receptor signaling complexes in vitro and the quantitative cell signaling studies at the single cell level using flow cytometry.

Another critical aspect of RTK signaling is precise temporal regulation of their activation, which involves both keeping their basal activity low and restricting signal duration upon ligand binding. We will apply cell-based high throughput screening assays for mapping these basal autoinhibitory interactions and identifying novel feedback regulators of the ErbB and MET receptors. We are also interested in understanding how receptor signaling is fine-tuned by the actin cytoskeleton and sites of cell adhesion. EGFR/ErbB1 directly binds actin and both ErbB receptors and MET were shown to interact with the integrins. The molecular basis for these interactions and their functional consequences for receptor signaling are unclear due to complexity stemming from analyzing these processes in cells. We will work on developing an in vitro system where interaction between actin polymers, adhesion molecules and the receptors reconstituted in the membranes can be studied directly. Such system will allow investigating the interplay between actin binding and polymerization, and receptor organization at the membrane, and will yield fundamental insight into the cross-talk between receptor tyrosine kinase signaling and actin-dependent processes, such as cell adhesion and motility.

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
Vascular & Cardiac Biology
Research Summary: 
Molecular basis for Receptor Tyrosine Kinase signaling across the plasma membrane

Websites

Publications: 

Publisher Correction: Evolution of enhanced innate immune evasion by SARS-CoV-2.

Nature

Thorne LG, Bouhaddou M, Reuschl AK, Zuliani-Alvarez L, Polacco B, Pelin A, Batra J, Whelan MVX, Hosmillo M, Fossati A, Ragazzini R, Jungreis I, Ummadi M, Rojc A, Turner J, Bischof ML, Obernier K, Braberg H, Soucheray M, Richards A, Chen KH, Harjai B, Memon D, Hiatt J, Rosales R, McGovern BL, Jahun A, Fabius JM, White K, Goodfellow IG, Takeuchi Y, Bonfanti P, Shokat K, Jura N, Verba K, Noursadeghi M, Beltrao P, Kellis M, Swaney DL, García-Sastre A, Jolly C, Towers GJ, Krogan NJ

Author Correction: Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface.

Nature

Diwanji D, Trenker R, Thaker TM, Wang F, Agard DA, Verba KA, Jura N

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.

Cell reports

Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.

Cell reports

Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM